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Abstract
Background: Current approaches in bone regeneration combine osteoconductive scaffolds with bioactive cytokines 
like BMP or VEGF. The idea of our in-vitro trial was to apply VEGF165 in gradient concentrations to an equine collagen 
carrier and to study pharmacological and morphological characteristics of the complex in a circulation model.
Methods: Release kinetics of VEGF165 complexed in different quantities in a collagen matrix were determined in a 
circulation model by quantifying protein concentration with ELISA over a period of 5 days. The structural changes of 
the collagen matrix were assessed with light microscopy, native scanning electron microscopy (SEM) as well as with 
immuno-gold-labelling technique in scanning and transmission electron microscopy (TEM).
Results: We established a biological half-life for VEGF165 of 90 minutes. In a half-logarithmic presentation the VEGF165 
release showed a linear declining gradient; the release kinetics were not depending on VEGF165 concentrations. After 
12 hours VEGF release reached a plateau, after 48 hours VEGF165 was no longer detectable in the complexes charged 
with lower doses, but still measurable in the 80 μg sample. At the beginning of the study a smear layer was visible on 
the surface of the complex. After the wash out of the protein in the first days the natural structure of the collagen 
appeared and did not change over the test period.
Conclusions: By defining the pharmacological and morphological profile of a cytokine collagen complex in a 
circulation model our data paves the way for further in-vivo studies where additional biological side effects will have to 
be considered. VEGF165 linked to collagen fibrils shows its improved stability in direct electron microscopic imaging as 
well as in prolonged release from the matrix. Our in-vitro trial substantiates the position of cytokine collagen complexes 
as innovative and effective treatment tools in regenerative medicine and and may initiate further clinical research.
Background
Osteogenesis
The human skeleton is subject to permanent remodelling
processes: 5% of the human skeleton is rebuilt per year.
This remodelling is an integral part also of the mecha-
nism of bone healing and regeneration of bony defaults.
In the process of bone healing and regeneration, bio-
chemical procedures follow a well-defined temporal and
territorial pattern. Resting chondrocytes start to prolifer-
ate, differentiate into hypertrophic chondrocytes, and
synthesise collagen and extracellular matrix.
Then blood vessels invade; osteogenesis takes place in
the vicinity of neo-vessels that mediate the delivery of
osteoprogenitors, secrete mitogen for osteoblasts, and
transport nutrients and oxygen. The cartilage matrix is
degraded and replaced with the typical trabecular bone
matrix produced by osteoblasts. Blood vessels provide a
conduit for the recruitment of cells involved in cartilage
resorption and bone deposition and are therefore a cru-
cial condition for any regeneration [1,2]. The process is
operated by a variety of cytokines as bone morphogenetic
proteins (BMPs) or vascular endothelial growth factor
(VEGF) [3,4].
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Page 2 of 7There are two basic options to support bone formation:
to enhance the remodelling processes by optimizing the
vascularization via application of potent angiogenetic
cytokines as VEGF or to implant a scaffold to provide a
matrix that induces bone regeneration [5,6].
VEGF165
VEGF is an important cytokine in the process of endo-
chondral bone development and mediating bone vascu-
larisation for normal differentiation of chondrocytes and
osteoblasts. An increase in VEGF is an indication of
increased vascular permeability and microvascular activ-
ity, including angiogenic growth of new blood vessels [7-
9].
VEGF is a homodimer glycoprotein, its family includes
6 related proteins; VEGF165 is most common and biologi-
cally active [10]. It is released by many cell populations as
fibroblasts, monocytes, macrophages or lymphocytes
[11]. The corresponding receptors belong to the tyrosine
kinase family. VEGF165 induces angiogenesis on different
levels: it acts as mitogen especially on endothelial cells,
raises the vessel permeability and dilatation by releasing
NO and has chemotactic impact on other growth pro-
moting cell populations [12]. The most potent stimulus
for VEGF165 synthesis is lack of oxygen. Under hypoxia an
increase in VEGF165 mRNA was shown and, in addition,
the RNA's half-life was extended. This effect is translated
by the hypoxia sensitive transcription factor HIF1. The
instantaneous angiogenetic effect of VEGF165 is the
increase in vessel permeability and mitogenic stimulation
of endothelial cells. According to its potential VEGF165 is
also involved in pathophysiological processes like tumour
growth; mainly in hypoxic tumour regions raised
VEGF165 levels were scored [13,14]. Disadvantageous for
a routine use are a difficult handling of the liquid applica-
tion form, its short half-life and susceptibility to light and
temperature.
Bone graft substitutes and collagen
Some of the common methods used to repair bony skele-
tal defects are autografts, allografts, or synthetic implant
materials. Yet, imperfections persist in these methods,
such as limited harvesting, the possibility of disease
transmission, poor biocompatibility, and the risk of pros-
thetic implantation failure. Therefore, alternative strate-
gies, such as tissue engineering approaches, are needed to
improve the treatment and quality of life of all patients.
The minimum requirements for bone graft substitutes
are:
• No cancerogenic effect
• No water-solubility
• Non-immunogenic effect
• Lacking of an inflammatory response
• Defined bio-degradation and
• Biocompatibility, namely of the surface.
Widely-used materials are hydroxylapatite and trical-
cium phosphate as synthetic inorganic bone graft substi-
tutes. They come with good biocompatibility and
osteoconductivity. Yet, they are brittle and not resilient in
functionally stressed areas [15-17]. The advantage of col-
lagen as a natural substitute is the fact that collagen is the
main constituent of organic bone matrix. Fitted in bony
defaults it is not degraded by but incorporated into the
regenerating tissue. It accelerates the healing process and
reduces the side effects of decomposition products
[18,19].
In innovative approaches the osteoconductive collage-
nous scaffold is combined with the osteoinductive impact
of cytokines like BMP or VEGF165. The objectives of our
study were to apply VEGF165 in gradient concentrations
to an equine collagen carrier and to study the complex in
a circulation model. The VEGF165 release kinetics should
be quantified and the morphological degradation of the
collagen-cytokine complex should be visualized.
Methods
VEGF165-collagen complex
Collagen I was purchased (Resorba, Nuernberg, Ger-
many) and liquefied. Human recombinant VEGF165 (R&D
Systems, Wiesbaden, Germany) was added in different
concentrations. The complexes were formed in hemi-
spheres and drugged with aldehyde to avoid the cross-
linking of collagen fibrils.
The total quantity of collagen was 5.6 mg/cm3 per
application, VEGF165 was added in 0.8 μg, 10 μg or 80 μg
quantities.
Circulation model
We used a digitally controlled peristaltic pump that deliv-
ered the medium with a mean flow rate of 27 ml per min-
ute (Cole Parmer Masterlex Console Drive Pump). As
aqueous solution a 0.2 mol PBS buffer was utilized in a
total quantity of 80 ml. Circulation was simulated under
constant conditions of 20°C and pH 7.2.
Lab report
The complexes were charged with VEGF165 in three dif-
ferent concentrations: 0.8 μg, 10 μg and 80 μg. Three
complexes of each concentration were incubated for 5
days. As a sample, the total volume of buffer medium was
extracted and analysed to avoid saturation of the buffer
medium with free VEGF165. To differentiate between the
initial degradation of our collagen complexes with a quick
VEGF165 release and the slow long-term saturation pro-
cess, we adopted an asymmetrical test pattern:
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and 24 hours. The next specimens were taken after day 2,
3, 4 and 5. VEGF165-free collagen complexes served as
negative controls and were analysed identically.
ELISA
VEGF165 concentrations were assessed by performing a
solid-phase VEGF165 Immunoassay (VEGF165 Quantikine,
DVE00, R&D Systems GmbH, Wiesbaden-Nordenstadt,
Germany). The ELISA was performed according to the
manufacturer's protocol; its sensitivity was described as <
9 pg/ml. The concentration of VEGF165 was expressed as
pg/ml.
VEGF165 was quantified by using a standard curve made
by human VEGF165 ranging from 31.2 pg/ml to 2000 pg/
ml. The chromogenic reaction was read at 415 nm
(Molecular Devices).
Light microscopy
Collagen samples were processed according to a standard
protocol. In short, they were fixed, dehydrated in increas-
ing gradients of ethanol and embedded in paraffin. Thin
sections were sliced, stained according to an azan stan-
dard procedure and fixed in methacrylate.
The sections were evaluated with a light microscope
(Zeiss Axioscop, Jena, Germany).
Scanning electron microscopy (SEM)
Samples were fixed in 3% glutaraldehyde in 0.1 mol phos-
phate buffered saline and then washed in the buffer (0.1
mol PBS). After rinsing, the samples were dehydrated in a
graded ethanol series and dried with a critical point dry-
ing. All dried samples were mounted on aluminium stubs
and sputter coated with coal to a coating thickness of 8
nm.
For immunohistochemical SEM analysis the sections
were fixed in 4% paraformaldehyde solution, rinsed with
0.1 mol PBS buffer and incubated with primary VEGF165-
specific antibodies at room temperature for 1 hour. After-
wards, the secondary immunogold-labelled antibody was
incubated at room temperature for 1 hour. Between incu-
bation steps phosphate buffered saline rinses were per-
formed. All antibodies were diluted according to the
manufacturers' instructions.
The gold particles as spheres of a 10 nm diameter were
easily detectable in scanning electron microscopy.
Transmission electron microscopy (TEM)
For TEM analysis the collagen samples were fixed in 3%
glutaraldehyde for 24 hours, rinsed in 0.1 mol phosphate
buffered saline and incubated in osmium acid for 1 hour.
Afterwards, the samples were dehydrated in a graded
ethanol series, embedded in araldite and sliced thin sec-
tions (1 μm). The slices were stained with tolouidin blue
following a standard procedure. Representative areas
were cut in ultra-thin slices of 70 nm, placed on copper
nets and analysed in transmission electron microscopy.
Immunohistochemical staining was performed as




To determine biological half-life of VEGF165 its dissolu-
tion in aqueous solution at room temperature was analy-
sed. VEGF165 collagen complexes charged with 10 μg of
VEGF165 were probed over 12 hours. Our results provide
a half-life of free VEGF165 of 90 minutes (Fig. 1).
VEGF165 release kinetics
In a half-logarithmic presentation the observed VEGF165
concentration showed a characteristic linear decline over
time. The gradients of the three VEGF165 doses were par-
allel and independent of VEGF165 concentration. VEGF165
release reached a plateau after 12 hours and was no lon-
ger detectable in the applications of 0.8 μg and 10 μg after
48 hours, whereas the complex charged with 80 μg of
VEGF165 still showed measurable cytokine release after
over 50 hours. Saturation effects of the buffer medium
were not observed (Fig. 2).
VEGF165 degradation
The efficiency describes the quotient of VEGF165 val-
ues scored in our test setting and initially applied
VEGF165. Only 10% of initially applied 0.8 μg were
finally detected in the present study. Ninety per cent
were lost during production, transport or storage. Of
the applied 10 μg and 80 μg, 96% respectively 97% were
lost (Fig. 3).
Figure 1 Half-life of VEGF.
Kleinheinz et al. Head & Face Medicine 2010, 6:17
http://www.head-face-med.com/content/6/1/17
Page 4 of 7Light microscopy
In light microscopy the VEGF165 collagen complex
appears homogenously, presents a reticular structure and
shows no signs of structural defaults caused by fixation or
coupling with VEGF165. Only in the periphery single
agglutinated fibres are detected; these are artefacts
caused by the production process (Fig. 4).
SEM
In scanning electron microscopy the VEGF165 collagen
complexes feature more agglutinated parts, even in cen-
tral areas, in contrast to the collagen matrix without
cytokine (Fig. 5a and 5b).
During the five days of degradation process the ultra
structure of the VEGF165 collagen complexes changes
considerably. On day 0, the collagen matrix is coated by a
VEGF165 layer that varnishes the single collagen fibrils.
After 3 days of simulated circulation the collagen fibres
are clearly detectable; this effect is more obvious on day
five. The collagen matrix appears porose and knotty (Fig.
6a and 6b).
With immuno-gold-labelling the VEGF165 molecules
are visible. A homogenous distribution of VEGF165 in the
collagen scaffold can be proved (Fig. 7).
TEM
In transmission electron microscopy the gold particles
present themselves as black round structures (Fig. 8). Sin-
gle VEGF antibody complexes can be precisely assigned
to their corresponding collagen fibril. Due to the close
vicinity between fibre and VEGF an adhesion must be
assumed that overcomes the preliminary chemical proce-
dure for TEM (Fig. 9).
Discussion
To restore form and function to an existing bony defect,
vascularisation is the key to success.
Clinical experience shows that avascular bony struc-
tures namely in chronically infected bones tend to atro-
phy and fracture [20].
Circulation and angiogenesis are responsible for a
restored perfusion of impaired bone areas.
Bone cells on the other hand release growth factors to
stimulate angiogenesis. Osteo- and angiogenesis are
clearly linked in a strong co-dependent relation. The high
susceptibility and the low applicable doses of cytokines
Figure 2 Release kinetics of VEGF.
Figure 3 Natural degradation of VEGF.
Figure 4 Collagen matrix, azan staining (100×): representative 
central area of pure collagen matrix.
Figure 5 Collagen matrix with (a) and without (b) VEGF, SEM 
(100×); the smear layer coffering the surface of the collagen ma-
trix can be seen on the left picture.
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easy application mode is critical for the successful use of
biomaterials for regenerative medicine strategies [21,22].
VEGF165 has been exposed as the central angiogenetic
protein in the process of bone regeneration; many in-
vitro studies underlined its potency to stimulate osteo-
genesis physiologically via induction of neo-vascularisa-
tion [23]. Xenogenic collagen is a well established drug
carrier in daily clinical use. As freeze-dried sponge it
comes with excellent biocompatibility and is hence the
ideal carrier for cytokine application.
In the present study the combination of a xenogenic
collagen carrier and recombinant human VEGF165 is anal-
ysed pharmacologically and morphologically. This kind
of research is crucial for forthcoming in-vivo studies
where biological factors will overlie and falsify the thera-
peutical effects of the VEGF165 collagen complex. To be
able to interpret these results properly drug release kinet-
ics has to be established before. In cell cultures the
VEGF165 specific half-maximum growth stimulation has
been determined. The effect of applied cytokines is sup-
posed to range above this score [24].
Our data accounts for VEGF165 release from the colla-
gen over 48 hours; considering the 90 minutes half-life of
free VEGF165 it is a surprising result. Obviously, a stabili-
sation of VEGF165 can be achieved by connecting the
cytokine with collagen fibrils. The trial at hand provides
only indirect evidence for this assumption but is observed
in the whole test series.
During the first 50 hours an elevated release rate was
observed as described in the literature before. The
VEGF165 release is divided in two phases: first, the quick
elusion of VEGF165 and diffusion into the buffer medium,
and second, the slow sustained disposal when the
VEGF165 molecules are dissolved from the degrading col-
lagen fibrils in the deeper areas of the matrix.
This pharmacological behaviour corresponds with our
morphological findings in REM: hydrolytic erosion
reveals the single collagen fibrils and facilitates VEGF165
release.
The fraction of released VEGF165 varies in our data
from 3% to 10%. Despite ideal test condition the main
Figure 6 VEGF165-collagen complex on day 3 (a) and day 5 (b), 
SEM (20000×).
A B 
Figure 7 VEGF165-collagen complex, 10 μg, TEM, (5000×).
Figure 8 VEGF165-collagen complex, 10 μg, TEM (3400×).
Figure 9 VEGF165-collagen complex, 10 μg, TEM, (21500×); a 
VEGF-antibody complex in relation to its collagen fibre.
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and storage.
The decreasing efficacy of the higher concentrated
VEGF165 carriers argues for a saturation effect, higher
doses of VEGF165 in the collagen scaffold do not lead to
higher VEGF165 release [6].
To sum up: The biphasic release kinetic allows a hyper-
physiological stimulation caused by the applied VEGF165
over 50 hours. It is more efficient than free VEGF165.
Higher doses of VEGF165 do not lead to better effects for
there is no proportional connection between the dose in
the collagen carrier and the emitted total quantity.
The next steps to elucidate the biological behaviour of
the cytokine collagen complex are in-vivo trials to elimi-
nate the shortcomings of our setting
- PBS as an inadequate model for blood flow in human
tissues
- disregard of enzymatic degradation processes
- insufficient verification of biologically active cytokine
areas
The interfacing of VEGF165 to a collagen scaffold is not
the only way of cytokine application: its transport in
micro spheres was described; cytokine mRNA was cou-
pled with a viral vector and cytokine plasmid DNA was
directly transferred into the tissue [25-27].
Conclusions
The restitution of bony defaults with a technique that
provides biologic functionality, easy mechanical handling
and reliable outcome is a significant challenge in maxillo-
facial surgery.
Our idea was to combine an osteoconductive scaffold
with osteoinductive proteins and hence to stimulate and
support natural healing and regenerating processes.
Our in-vitro trial substantiates the position of cytokine
collagen complexes as innovative and effective treatment
tools in regenerative medicine and paves the way for fur-
ther clinical research.
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